Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 195-203 , February 2006

Consolidation with High-Dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-Free Survival in Hormone-Insensitive Metastatic Breast Cancer in Complete Remission Compared with Intensive Standard-Dose Chemotherapy Alone

Presented at the San Antonio Breast Cancer Meeting, December 3, 1996.

  • James J. Vredenburgh

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationCorrespondence and reprint requests: James J. Vredenburgh, MD, Duke University Medical Center, Box 3624, Durham, NC 27710
    • ,
  • David Coniglio

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Gloria Broadwater

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Roy B. Jones

      Affiliations

    • Anderson Cancer Center, Houston, Texas
    • ,
  • Maureen Ross

      Affiliations

    • University of Virginia, Charlottesville, Virginia
    • ,
  • Elizabeth J. Shpall

      Affiliations

    • Anderson Cancer Center, Houston, Texas
    • ,
  • Atif Hussein

      Affiliations

    • Memorial Regional Cancer Center, Hollywood, Florida
    • ,
  • David Rizzieri

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Larry B. Marks

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Colleen Gilbert

      Affiliations

    • Critical Thinking Co., Cary, North Carolina
    • ,
  • Mary Lou Affronti

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Sarah Moore

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Carolyn McDonald

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • William P. Petros

      Affiliations

    • University of West Virginia, Morgantown, West Virginia
    • ,
  • William P. Peters

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • Adherex Inc., Durham, North Carolina

Received 28 January 2005 ,Accepted 24 October 2005.

References 

  1. Jemal A , Murray T , Samuels A , Ghafoor A , Ward E , Thun MJ . Cancer statistics, 2003 . CA Cancer J Clin . 2003;55:5–26
  2. Costanza ME , Weiss RB , Henderson IC , et al.   Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients (report of a randomized study—Cancer and Leukemia Group B 8642) . J Clin Oncol . 1999;17:1397–1406
  3. Rahman ZU , Frye DK , Smith TL , et al.   Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy (a reference) . Cancer . 1999;85:104–111
  4. Paridaens R , Biganzoli L , Bruning P , et al.   Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer (a European Organization for Research and Treatment of Cancer randomized study with cross-over) . J Clin Oncol . 2000;18:724–733
  5. Loesch D , Robert N , Asmar L , et al.   Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer . J Clin Oncol . 2002;20:3857–3864
  6. Clark GM , Sledge GW , Osborne CK , McGuire WL . Survival from first recurrence (relative importance of prognostic factors in 1,015 breast cancer patients) . J Clin Oncol . 1987;5:55–61
  7. Falkson G , Gelman RS , Leone L , Falkson CI . Survival of premenopausal women with metastatic breast cancer (Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group studies) . Cancer . 1990;66:1621–1629
  8. Sparano JA , Hu P , Rao RM , Falkson CI , Wolff AC , Wood WC . Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer (an Eastern Cooperative Oncology Group Study) . J Clin Oncol . 1999;17:3828–3834
  9. Antman K , Ayash L , Elias A , et al.   A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy . J Clin Oncol . 1992;10:102–110
  10. Laport GF , Grad G , Grinblatt DL , Bitran JD , Williams SF . High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer (a 10-year experience) . Bone Marrow Transplant . 1998;21:127–132
  11. Dunphy F , Spitzer G , Fornoff J , et al.   Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support . Cancer . 1994;73:2157–2167
  12. Ayash L , Wheeler C , Fairclough D , et al.   Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer . J Clin Oncol . 1995;13:2043–2049
  13. Vahdat LT , Balmaceda C , Papadopoulos K , et al.   Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer . Bone Marrow Transplant . 2002;30:149–155
  14. Rahman ZU , Frye DK , Buzdar AU , et al.   Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer . J Clin Oncol . 1997;15:3171–3177
  15. Jones RB , Shpall EJ , Shogan J , et al.   The Duke AFM Program (Intensive induction chemotherapy for metastatic breast cancer) . Cancer . 1990;66:431–436
  16. Peters WP , Ross M , Vredenburgh JJ , et al.   High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer . J Clin Oncol . 1993;11:1132–1143
  17. Peters WP , Rosner G , Ross M , et al.   Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy . Blood . 1993;81:1709–1719
  18. Eder JP , Antman K , Peters WP , et al.   High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer . J Clin Oncol . 1986;4:1592–1597
  19. Carter DL , Marks LB , Bean JM , et al.   Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue . J Clin Oncol . 1999;17:887–894
  20. Kaplan EL , Meier P . Nonparametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457–481
  21. Peto R , Pike MC , Armitage P , et al.   Design and analysis of randomized clinical trials requiring prolonged observation of each patient . Br J Cancer . 1977;31:7–9
  22. Rizzieri DA , Vredenburgh JJ , Jones R , et al.   Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support . J Clin Oncol . 1999;17:3064–3074
  23. Sayer HG , Schilling K , Vogt T , et al.   Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer . J Cancer Res Clin Oncol . 2003;129:361–366
  24. Somolo G , Chow W , Hamasaki V , et al.   Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies . Biol Blood Marrow Transplant . 2001;7:284–293
  25. Greenberg PAC , Hortobagyi GN , Smith TL , Ziegler LD , Frye DK , Buzdar AU . Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer . J Clin Oncol . 1996;14:2197–2205
  26. O’Shaughnessy J , Miles D , Vukelja S , et al.   Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer (phase III trial results) . J Clin Oncol . 2002;20:2812–2823
  27. Stadtmauer EA , O’Neill A , Goldstein LJ , et al.   Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer . N Engl J Med . 2000;342:1069–1076
  28. Berry D , Broadwater G , Klein J , et al.   High-dose versus standard chemotherapy in metastatic breast cancer (comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry) . J Clin Oncol . 2002;20:743–750
  29. Pedrazzoli P , Ferrante P , Kulecki A , et al.   Autologous hematopoietic stem cell transplantation for breast cancer in Europe (critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999) . Bone Marrow Transplant . 2003;32:489–494
  30. Elias AD , Ibrahim J , Richardson P , et al.   The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue (an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program) . Biol Blood Marrow Transplant . 2002;8:198–205

PII: S1083-8791(05)00684-1

doi: 10.1016/j.bbmt.2005.10.009

Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 195-203 , February 2006

Article Tools

* Image Usage & Resolution